François Ravat (Saint-Luc Saint-Joseph), Patrick Jault (Percy) and Jérôme Gabard (Pherecydes Pharma) wrote a scientific article entitled "Bactériophage et phagothérapie : utilisation de virus naturels pour traiter les infections bactériennes - Using Natural Viruses To Treat Bacterial Infections". This article was published in the journal Annals of Burn & Fire Disasters, 2015; 23(1):13-20.
A documentary about Pherecydes Pharma and its products to treat burned patients ( Phagoburn project ) was released February 7, 2015 in Future mag on the Arte channel.
The newspaper LesEchos.fr published in January 2015 an article on Pherecydes Pharma and Phagoburn project.
PHOSA is a French research project to develop a bacteriophage cocktail to fight against osteoarticular bacterial infections caused by Staphylococcus aureus and epidermidis.
Jérôme Gabard: CEO
|Starting at the bench in DuPont de Nemours plant biotechnology research facility (Wilmington, DE, USA) in the late eighties, Jérôme has been since developing professional skills in marketing and business development.
Prior to join Pherecydes Pharma he was Life Sciences Director at The Marketech Group, to develop company sales and to perform strategic and operational market research studies for start up’s or big pharma.
He is experienced in managing private innovative R&D start up’s (Euroclide) and to build value through merger-acquisition (Faust Pharmaceuticals, today Domain Therapeutics).
During his career he has been involved in a variety of R&D industrial projects, related to plant biotechnology, crop protection, food pathogen diagnostics, information management and drug discovery